To include your compound in the COVID-19 Resource Center, submit it here.

Novavax gains on DSMB analysis for RSV vaccine

Novavax Inc. (NASDAQ:NVAX) jumped $0.79 (59%) to $2.12 on Wednesday after presenting results from an "informational analysis" of

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE